Show simple item record

dc.creatorBaretić, Maja
dc.date.accessioned2020-08-24T23:11:52Z
dc.date.available2020-08-24T23:11:52Z
dc.date.created2020-08
dc.identifier.issn1871-4021spa
dc.identifier.otherhttps://www.sciencedirect.com/science/article/pii/S1871402120300795?via%3Dihubspa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/12181
dc.format.extent2 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherDiabetes & Metabolic Syndrome: Clinical Research & Reviewsspa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectDiabetesspa
dc.titleCase report of chloroquine therapy and hypoglycaemia in type 1 diabetes: What should we have in mind during the COVID-19 pandemic?spa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/embargoedAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.rights.localAcceso restringidospa
dc.subject.keywordType 1 diabetesspa
dc.subject.keywordChloroquinespa
dc.subject.keywordHypoglycaemiaspa
dc.subject.keywordRemissionspa
dc.identifier.doihttps://doi.org/10.1016/j.dsx.2020.04.014spa
dc.description.abstractenglishA type 1 diabetes patient experienced remission associated with chloroquine therapy while travelling to a malaria-endemic area. Chloroquine has immunomodulatory and hypoglycaemic effects and may become more frequently used due to the COVID-19 pandemic. Patients with type 1 diabetes treated with chloroquine should be monitored for hypoglycaemia, even after recovery.spa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record